Alexander Iskander
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Alexander Iskander has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Bela Peethambaran
Department of Biology, St. Joseph’s University, Philadelphia, PA 19131, USA
1 shared publication - Christina Scanlon
Department of Biological Sciences, University of the Sciences, 600 S 43rd St, Philadelphia, PA 19104, USA
1 shared publication - Salma Maher
Department of Biological Sciences, University of the Sciences, 600 S 43rd St, Philadelphia, PA 19104, USA
1 shared publication - Thư Lê
Department of Biological Sciences, University of the Sciences, 600 S 43rd St, Philadelphia, PA 19104, USA
1 shared publication - Varsha Sivaganesh
Department of Biological Sciences, University of the Sciences, 600 S 43rd St, Philadelphia, PA 19104, USA
1 shared publication - Vignesh Sivaganesh
Department of Biological Sciences, University of the Sciences, 600 S 43rd St, Philadelphia, PA 19104, USA
1 shared publication
Latest Publications
- Open Access
- 28 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (23) , 12865
Protein Tyrosine Phosphatases: Mechanisms in Cancer
Protein tyrosine kinases, especially receptor tyrosine kinases, have dominated the cancer therapeutics sphere as proteins that can be inhibited to selectively target cancer. However, protein tyrosine phosphatases (PTPs) are also an emerging target. Though historically known as negative regulators of the oncogenic tyrosine kinases, PTPs are now known to be both tumor-suppressive and oncogenic. This review will highlight key protein tyrosine phosphatases that have been thoroughly investigated in various cancers. Furthermore, the different mechanisms underlying pro-cancerous and anti-cancerous PTPs will also be explored.
- 28 November 2021
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (23) , 12865
Open AccessProtein Tyrosine Phosphatases: Mechanisms in Cancer
Protein tyrosine kinases, especially receptor tyrosine kinases, have dominated the cancer therapeutics sphere as proteins that can be inhibited to selectively target cancer. However, protein tyrosine phosphatases (PTPs) are also an emerging target. Though historically known as negative regulators of the oncogenic tyrosine kinases, PTPs are now known to be both tumor-suppressive and oncogenic. This review will highlight key protein tyrosine phosphatases that have been thoroughly investigated in various cancers. Furthermore, the different mechanisms underlying pro-cancerous and anti-cancerous PTPs will also be explored.